Background Individuals infected with SARS-CoV-2 develop neutralising antibodies. We investigated the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how this proportion varies with selected covariates. Methodology/Principal findings This systematic review and meta-analysis examined the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how these proportions vary with selected covariates. Three models using the maximum likelihood method assessed these proportions by study group, covariates and individually extracted data (protocol CRD42020208913). A total of 983 reports were identified and 27 were included. The pooled (95%CI) proportion of individuals with neutralising antibodies was 85.3% (83.5–86.9) using the titre cut off >1:20 and 83.9% (82.2–85.6), 70.2% (68.1–72.5) and 54.2% (52.0–56.5) with titres >1:40, >1:80 and >1:160, respectively. These proportions were higher among patients with severe COVID-19 (e.g., titres >1:80, 84.8% [80.0–89.2], >1:160, 74.4% [67.5–79.7]) than those with mild presentation (56.7% [49.9–62.9] and 44.1% [37.3–50.6], respectively) and lowest among asymptomatic infections (28.6% [17.9–39.2] and 10.0% [3.7–20.1], respectively). IgG and neutralising antibody levels correlated poorly. Conclusions/Significance 85% of individuals with proven SARS-CoV-2 infection had detectable neutralising antibodies. This proportion varied with disease severity, study setting, time since infection and the method used to measure antibodies. Author summary Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) elicits adaptive immunological responses, including immunoglobulins A, M, and G and neutralising antibodies. Neutralising antibodies are considered markers of functional immunity and protection. However, not all individuals with proven infections have detectable neutralising antibodies. In this systematic review, we investigated the proportion of individuals with former SARS-CoV-2 infections who develop neutralising antibodies, whether their titres vary with disease severity, and their correlation with Immunoglobulin G. We found that approximately 85% of individuals with SARS-CoV-2 infection have detectable neutralising antibodies. This proportion was higher among patients with severe Coronavirus Disease 19 and lower in asymptomatic infections. The variation across studies reflected the wide range of methods used to measure both immunoglobulins and neutralising antibodies, and highlight the need for an international reference standard to measure SARS-CoV-2 antibodies.
【초록키워드】 coronavirus disease, Meta-analysis, antibodies, SARS-CoV-2, IgG, protocol, adaptive, severe COVID-19, Immunity, antibody, SARS-COV-2 infection, disease severity, immunoglobulins, Neutralising Antibodies, Variation, Infection, systematic review, severe acute respiratory syndrome coronavirus-2, asymptomatic infections, Severe acute respiratory syndrome, Immunoglobulin G, SARS-CoV-2 antibodies, Immunoglobulin, neutralising antibody, International, Patient, asymptomatic infection, immunological responses, Mild, covariates, respiratory, correlation, SARS-CoV-2 infections, reference standard, marker, study group, 95%CI, titres, severe coronavirus disease, Author, individual, titre, covariate, likelihood, SARS-CoV-2 neutralising antibodies, highlight, lowest, selected, develop, examined, proportion, investigated, detectable, functional, reflected, correlated, elicit, cut off, infected with SARS-CoV-2, SARS-CoV-2 neutralising antibody, 【제목키워드】 SARS-CoV-2, systematic review, acute infection, neutralising antibody,